Skin Graft Fraud Litigation: The Three Fronts That Open at Once

By Reynaldo T. Acosta, Esq., Head of Litigation, Vitale, Suarez & Associates, P.A. · Miami Lakes, Florida

Skin graft fraud litigation is not one case with one deadline. It is three proceedings that tend to open within weeks of each other, each with a different opponent, a different standard of proof, and a different consequence for anything you say in the other two. If you are a wound care provider, a podiatrist, a nurse practitioner or a clinic owner who applied high-cost skin substitutes and billed Medicare for them, the risk you need to plan for is not a single lawsuit. It is the interaction between three.

The three fronts are a payment front, where a Medicare contractor recoups money it already paid you; a commercial front, where the product’s seller or distributor sues you for unpaid invoices; and a government front, where the Department of Justice or the Office of Inspector General investigates the billing, often beginning with a civil investigative demand rather than a complaint. Each is survivable. What causes disproportionate damage is defending them as if they were unrelated.

What Changed on January 1, 2026, and Why It Matters to a Case About 2023

Before the litigation posture makes sense, the payment history has to.

Until the end of 2025, most skin substitutes were paid as though they were biologicals. The Centers for Medicare & Medicaid Services described the mechanism in its fact sheet for the CY 2026 Physician Fee Schedule final rule: “most skin substitutes are paid as if they are biologicals under the average sales price (ASP)-based payment methodology described in section 1847A of the Social Security Act. Using this methodology, each skin substitute product receives a unique billing code and payment limit.”

The Office of Inspector General put the same point more bluntly in a report issued September 3, 2025: “For payment purposes, CMS treats skin substitutes like approved prescription biologics and skin substitutes are reimbursed in non-institutional Part B settings at 106 percent of the average sales price (ASP).”

Payment at a percentage of a price the manufacturer itself reports creates an obvious incentive, and the spending record reflects it. CMS states that Part B spending on these products “rose from $252 million in 2019 to over $10 billion in 2024, a nearly 40-fold increase”, and adds that “Most of that increase is directly attributable to increases in payment rates and launch prices for skin substitute products.” MedPAC, commenting on the proposed rule in September 2025, noted that “the skin-substitute class rose sharply in rank by total Medicare spending from tenth in 2021 to second in 2024.”

Then it stopped. Under the CY 2026 Physician Fee Schedule final rule (CMS-1832-F, 90 FR 49266, effective January 1, 2026), CMS finalized paying “for skin substitute products as incident-to supplies when they are used as part of a covered application procedure paid under the PFS in the non-facility setting or under the OPPS in the hospital outpatient department setting.” The companion outpatient rule did the same in the hospital and ambulatory surgical center settings, creating separate payment groups by product category. The Department of Justice summarized the practical effect in June 2026: CMS “separately realigned payment, reducing Medicare’s payment to $127 per square centimeter starting on January 1, 2026.”

Approximately one hundred twenty-seven dollars per square centimeter, where the OIG’s own work plan describes historical prices “ranging from approximately $100 to more than $1,000 per square centimeter.”

Why this matters in a case about older claims. The rate change is prospective. It does not reprice a 2023 claim, and it is not a finding that any past claim was improper. But it does two things to your litigation. It tells you the spending pattern is now documented in the government’s own rulemaking, which means an investigator does not have to build the macro story from scratch. And it establishes a before-and-after that a reviewer will use as a frame, fairly or not, when looking at volume and pricing from the prior period. The context for that shift is set out in the payment change and its impact on providers.

Front One: The Clawback

The first thing most providers experience is not a lawsuit. It is money leaving.

A Medicare Administrative Contractor pays claims, reviews them afterward, determines an overpayment, and recovers it — frequently by offsetting future payments rather than sending an invoice. For a practice whose receivables are concentrated in one product line, that offset is a solvency event before it is a legal one.

The recoupment rules give you a limited pause, and it is narrower than providers assume. Under 42 C.F.R. § 405.379, contractors “can begin recoupment no earlier than 41 days from the date of the initial overpayment demand”, and a timely, valid request for redetermination causes the contractor to cease recoupment. A timely, valid request for reconsideration does the same at the second level.

And then the protection ends. Section 405.379(d)(5) is explicit: “if the provider or supplier subsequently appeals the overpayment to the ALJ, the Medicare Appeals Council, or Federal court, recoupment remains in effect.” Recoupment resumes after an unfavorable redetermination “On the 60th calendar day after the date of the notice of redetermination”, and under § 405.379(d)(9), “Interest accrues and is payable in accordance with the provisions of § 405.378.”

Read those provisions together and the strategic point emerges. The stay exists at the two levels that come fastest and disappears at the level where you first get a hearing. A provider who plans to win at the administrative law judge stage needs to plan for operating without the withheld money while getting there. How the clawback machinery works, and where it can be attacked, is examined in Medicare payment clawbacks in wound care.

Front Two: The Distributor’s Collection Suit

This is the front that surprises people, because the plaintiff is the company that sold you the product.

Writing in September 2026, Texas health law attorney Martin Merritt described the sequence from the defense side: a distributor bills a provider at a price far above what comparable products cost, Medicare pays the resulting claims, a contractor then recoups the payments, and the distributor sues the provider for the unpaid invoices — a judgment the provider cannot satisfy, because the money that would have paid the invoice has already been taken back. Merritt further reports that the distributor’s collection suit is frequently followed by a federal civil investigative demand examining the seller’s business practices.

Those are observations from his practice rather than published data, and they should be read that way. But the structure they describe is consistent with what the Department of Justice has alleged publicly. In its June 23, 2026 national health care fraud takedown, the Department announced that “Charges were filed against 11 defendants, including a company executive and eight medical professionals, across six districts in connection with billions of dollars in fraudulent claims for amniotic wound allografts”, and characterized the driver as follows: “This significant spike in allograft billings was alleged to have been driven not by medical necessity, but by a kickback scheme that generated substantial profit margins and lavish lifestyles for marketers and providers who participated.”

Note where the seller sits in that description. The distribution chain is part of the government’s theory, not an incidental detail — and a collection lawsuit is a public filing that maps the chain. The dynamics of that case, and what a provider should and should not concede in it, are the subject of what happens when the skin substitute distributor sues you.

Front Three: The Government Matter, Which Usually Starts Quietly

Federal exposure in this area rarely announces itself with a complaint. It starts with a demand for information.

Under 31 U.S.C. § 3733, the Attorney General or a designee may issue a civil investigative demand “before commencing a civil proceeding under section 3730(a) or other false claims law, or making an election under section 3730(b)” — that is, before any case exists and before the government decides whether to take over a sealed whistleblower suit. A demand may require the recipient to produce documents, “answer in writing written interrogatories”, “give oral testimony”, or “furnish any combination of such material, answers, or testimony.”

The provision that matters most to a wound care provider is who can receive one. The statute reaches “any person” who may hold relevant material. You do not have to be the target. A provider who bought product from a distributor under investigation can receive a demand about the distributor’s practices — and everything produced in response is available to the government in its own analysis, and can be shared with other agencies “in furtherance of its statutory responsibilities” under § 3733(i)(2).

If you intend to challenge a demand, the window is short. Section 3733(j)(2) permits a petition to modify or set it aside “within 20 days after the date of service of the civil investigative demand, or at any time before the return date specified in the demand, whichever date is earlier.” Twenty days, or sooner if the return date comes first. What a demand is and how a response gets organized is set out in civil investigative demands.

The substantive statute behind the demand is the False Claims Act, and two features of it drive the exposure in this field. Under 31 U.S.C. § 3729(b)(1), “knowingly” covers a provider who “has actual knowledge of the information”, one who “acts in deliberate ignorance of the truth or falsity of the information”, and one who “acts in reckless disregard of the truth or falsity of the information” — and the definition “require no proof of specific intent to defraud.”

Deliberate ignorance and reckless disregard are the standards a provider needs to think about, because they reach the physician who accepted a distributor’s representations about coverage without checking them. And the remedy is not limited to the money: § 3729(a)(1) provides for “a civil penalty of not less than $5,000 and not more than $10,000, as adjusted by the Federal Civil Penalties Inflation Adjustment Act of 1990…plus 3 times the amount of damages which the Government sustains.”

There is also a reverse-false-claims theory that specifically fits the clawback scenario. Section 3729(a)(1)(G) reaches a person who “knowingly conceals or knowingly and improperly avoids or decreases an obligation to pay or transmit money or property to the Government”, and § 3729(b)(3) defines “obligation” broadly as “an established duty, whether or not fixed.” An identified overpayment that is not addressed does not stay a payment problem indefinitely. That transition is examined in how unresolved overpayments become False Claims Act exposure.

The Interaction Is the Real Problem

Any one of these three is a manageable matter with competent counsel. The damage comes from the seams between them.

A pleading in the collection case can become evidence in the federal one. An answer that blames the distributor for misrepresenting coverage is a natural defense to a contract claim. It also concedes that you relied on a seller’s representation about Medicare coverage rather than an independent medical necessity determination — which is precisely the reliance that a deliberate-ignorance theory is built on.

An appeal brief can do the same in reverse. A redetermination submission arguing that the product was medically necessary for each patient is the right argument at the payment level. If it is drafted without regard to what the government will read, it becomes a set of sworn positions about volume, wound size and clinical decision-making that are difficult to revise later.

Discovery in a private lawsuit is not private. Documents produced to a distributor’s counsel, deposition testimony about how product was selected, and communications with sales representatives all become records that exist and can be obtained.

And timing runs in only one direction. The clawback has 41-day and 60-day features. The civil investigative demand has a 20-day window to challenge. The collection suit has a state-court answer deadline. None of them waits for the others, and the earliest deadline usually falls in the matter that seems least serious.

The practical implication is a single coordinated defense with one factual narrative, tested against all three audiences before anything is filed anywhere.

What Actually Gets Examined

Across all three fronts, the same documentary questions recur. They are worth auditing now rather than after a demand arrives.

Medical necessity, patient by patient. The Department of Justice’s 2025 takedown announcement described allografts allegedly “applied without coordination with the patients’ treating physicians, without proper treatment for infection, to superficial wounds that did not need this treatment, and to areas that far exceeded the size of the wound.” Each of those is a documentary question with a documentary answer: wound measurements over time, infection management, coordination with the treating physician, and the clinical basis for the product chosen. The standard is discussed in medical necessity for wound care.

Product quantity against wound size. Application to an area exceeding the wound, and the handling of unused product, are among the most arithmetically provable findings available to a reviewer. See skin substitute wastage.

The product’s regulatory category. Under 21 C.F.R. § 1271.10(a), a human cell, tissue or cellular and tissue-based product is regulated solely under section 361 of the Public Health Service Act only if it satisfies four criteria, including that it is “minimally manipulated” and “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent.” The FDA states that “For HCT/Ps not meeting the criteria established in Section 1271.10, FDA premarket review (including a license, approval, or clearance) is required.” A provider is not the manufacturer and is not responsible for the product’s regulatory status — but the category the product actually occupies now affects how it is paid and how it is characterized. See the 361 HCT/P and 510(k) pathways.

Your relationship with the seller. Rebates, marketing arrangements, volume-linked terms, free product, and anything resembling remuneration tied to referrals or ordering. The Department’s public allegations in this area consistently center on kickbacks.

Where the service was delivered. The OIG found that “Among enrollees with a skin substitute claim, costs for those reportedly treated at home were four times as high as those treated in an office setting.” A home-based model is lawful. It is also a documented outlier characteristic, which means the file supporting it needs to be better than average rather than thinner.

Immediate Response Checklist

Preserve everything and instruct your staff in writing to preserve it: charts, wound photographs and measurements, purchase orders, invoices, communications with sales representatives, and claim submissions. Identify which of the three fronts is actually open and read every deadline off the document that created it. Route all external communication through one person. Instruct staff not to volunteer explanations by phone or email — an informal remark that a note “must have been completed later,” or that “this is how the rep told us to bill it,” lands in a file that may be read by an investigator. Assemble the medical necessity record patient by patient rather than in the aggregate. Model your cash position with the offset in place at thirty, sixty and ninety days. And do not amend or supplement a chart after notice: retrospective documentation converts a coverage dispute into a question about the integrity of the record, which is the line examined in the difference between a billing error and an allegation of fraud.

When Early Counsel Is Not Optional

Two features of this area make early legal involvement a practical necessity rather than a preference.

The first is the coordination problem. Three proceedings with three opponents, three standards and three deadlines cannot be defended separately without one of them undermining another.

The second is privilege. Where counsel directs the internal review, communications about suspected legal exposure, record analysis and response strategy may be better protected than informal exchanges among clinical, billing and administrative staff. That protection depends on the facts and on how the review is structured, which is a reason to structure it deliberately at the outset.

Vitale, Suarez & Associates, P.A. has represented healthcare providers and other defendants in wound care and skin substitute matters, including audit and overpayment proceedings, commercial disputes with product suppliers, and government investigations. Nothing in this article describes any particular client, matter, or outcome. The firm’s practice in defense investigations, Medicare and Medicaid fraud defense and Medicare and Medicaid overpayments is described among its practice areas, and the compliance-side view of this same enforcement environment is set out in fraud risks and provider-specific challenges in skin substitute billing.

Frequently Asked Questions

What is skin graft fraud litigation?
It is shorthand for the group of proceedings that arise from billing Medicare for high-cost skin substitutes: post-payment recoupment by a Medicare contractor, commercial litigation with the product’s seller or distributor, and civil or criminal investigation under the False Claims Act and related statutes. They frequently run at the same time.

Did the January 2026 payment change make past claims improper?
No. The CY 2026 payment policy is prospective and does not reprice earlier claims or determine that any particular past claim was improper. It does mean the spending pattern is now documented in the government’s own rulemaking, which affects the context in which earlier periods get reviewed.

Can we receive a civil investigative demand if we are not the target?
Yes. Under 31 U.S.C. § 3733(a)(1), a demand may be issued to “any person” who may hold documentary material or information relevant to a false claims law investigation. Providers do receive demands concerning a distributor’s practices.

Does appealing an overpayment stop the recoupment?
Only at the first two levels. Under 42 C.F.R. § 405.379, a timely, valid request for redetermination and then for reconsideration causes recoupment to cease, but § 405.379(d)(5) provides that recoupment remains in effect once the matter goes to an administrative law judge, the Medicare Appeals Council, or federal court.

Does the government have to prove we intended to defraud?
Not under the False Claims Act. Section 3729(b)(1) defines “knowingly” to include deliberate ignorance and reckless disregard of the truth or falsity of the information, and states that the definitions “require no proof of specific intent to defraud.” Criminal charges involve different and higher standards.

Are the cases the Department of Justice has announced final?
No. Charges and allegations described in Department of Justice announcements are accusations. A charge is not a conviction, and every defendant is presumed innocent unless and until proven guilty.

The decision rule is simple: before you file anything in any one of the three proceedings, read the draft as the opponent in the other two would read it. A defense that wins the smallest case and damages the largest one is not a defense.

This article is for general information purposes only and should not be taken as legal advice for any individual case or situation. Reading it, or corresponding with us through this site, is not intended to create and does not create an attorney-client relationship. Federal and Florida healthcare regulations change frequently, and how any rule applies depends on the specific facts of your arrangement, your payor contracts, and your jurisdiction. Vitale, Suarez & Associates, P.A. is based in Miami Lakes, Florida and represents clients in Florida. If you have received an audit notice, records request, subpoena, civil investigative demand, or overpayment demand, speak with a licensed attorney before you respond.

Past results do not guarantee or predict a similar outcome in any future matter. Every case depends on its own facts. Charges and allegations referenced in government announcements are accusations only; a charge is not a conviction.

About the author. Reynaldo T. Acosta heads the litigation practice at Vitale, Suarez & Associates, P.A. in Miami Lakes, Florida, the firm founded in 1982 as The Health Law Offices of Anthony C. Vitale, P.A. He is a member of The Florida Bar and earned his J.D. from Florida International University College of Law, where he was named to the Dean’s List and competed on the International Commercial Arbitration and the Negotiation and Mediation teams. He also holds a B.S. in Criminal Justice and Public Management with a minor in Political Science from Florida International University, and advanced certifications in generative artificial intelligence, machine learning, and agentic systems from IBM, Anthropic, and Microsoft. He is a member of the American Bar Association, the Hispanic National Bar Association, and the Cuban American Bar Association, and works with clients in English and Spanish. More about the firm and its attorneys is available on the firm’s About page.

Contact Our Healthcare Lawyers Today!

Schedule a Consultation: (305) 358-4500

Contact Us
Vitale, Suarez & Associates, P.A.
8100 Oak Ln Suite 403
Miami Lakes, FL 33016
Phone: (305) 358-4500
Fax: (305) 358-5113
Email: info@vitalehealthlaw.com
Hours: Monday through Friday, 9:00 a.m. to 5:00 p.m.
The firm’s attorneys work with clients in English and Spanish.